SolGold Plc (LON:SOLG)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	-34.4	-60.3	-50.34	-1.59	-23.56	-14.07
Depreciation & Amortization	0.25	8.68	-2.42	4.48	1.47	0.9
Loss (Gain) From Sale of Assets	0.08	0.09	-	-	-	-
Stock-Based Compensation	1.93	2.16	1	0.45	0.32	1.16
Other Operating Activities	22.88	39.51	10.4	-17.7	8.37	2.76
Change in Accounts Receivable	-1.56	0.42	0.6	2.98	0.18	-0.34
Change in Accounts Payable	-0.33	-1.72	5.66	0.37	0.12	0.49
Operating Cash Flow	-10.63	-10.24	-33.66	-11.01	-13.11	-9.1
Capital Expenditures	2	-0.24	-1.67	-2.2	-6.28	-4.9
Cash Acquisitions	-	-	1.05	-	-	-
Investment in Securities	0.14	0.14	-	-	-	-
Other Investing Activities	-25.14	-25.14	-43.3	-69.46	-76.43	-54.47
Investing Cash Flow	-23	-25.24	-43.92	-71.65	-82.71	-59.37
Short-Term Debt Issued	-	10	-	-	-	14.82
Long-Term Debt Issued	-	-	50	-	84.38	-
Total Debt Issued	10	10	50	-	84.38	14.82
Long-Term Debt Repaid	-	-0.45	-0.23	-0.45	-0.44	-0.71
Net Debt Issued (Repaid)	-0.41	9.55	49.77	-0.45	83.94	14.1
Issuance of Common Stock	-	-	36	-	76.11	62.7
Other Financing Activities	49.38	-0.49	-1.66	-0.04	-2.65	-1.72
Financing Cash Flow	48.97	9.05	84.11	-0.49	157.4	75.08
Foreign Exchange Rate Adjustments	-0.05	-0.02	-0.15	-0.32	1.08	-1.46
Net Cash Flow	15.29	-26.45	6.38	-83.46	62.67	5.15
Free Cash Flow	-8.63	-10.48	-35.34	-13.2	-19.39	-14
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01
Levered Free Cash Flow	-16.42	-15.01	-19.18	-16.1	-26.75	-12.17
Unlevered Free Cash Flow	-2.74	-3.57	-10.94	-8.24	-20.47	-11.9
Change in Net Working Capital	-3.46	0.31	-6.17	-2.41	7.38	0.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.